Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)

Compare
14.53
-0.02
(-0.14%)
As of 1:20:05 PM GMT+8. Market Open.
Loading Chart for 603858.SS
  • Previous Close 14.55
  • Open 14.53
  • Bid 14.53 x --
  • Ask 14.54 x --
  • Day's Range 14.46 - 14.60
  • 52 Week Range 13.83 - 19.70
  • Volume 1,441,930
  • Avg. Volume 4,985,158
  • Market Cap (intraday) 16.071B
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) -0.26
  • Earnings Date --
  • Forward Dividend & Yield 0.13 (0.87%)
  • Ex-Dividend Date Aug 20, 2024
  • 1y Target Est --

Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. The company offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. Shandong Buchang Pharmaceuticals Co., Ltd. was founded in 1993 and is based in Heze, China.

www.buchang.com

8,311

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603858.SS

View More

Performance Overview: 603858.SS

Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603858.SS
8.04%
SSE Composite Index (000001.SS)
1.86%

1-Year Return

603858.SS
12.38%
SSE Composite Index (000001.SS)
7.31%

3-Year Return

603858.SS
19.57%
SSE Composite Index (000001.SS)
6.81%

5-Year Return

603858.SS
20.38%
SSE Composite Index (000001.SS)
16.36%

Compare To: 603858.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603858.SS

View More

Valuation Measures

Annual
As of 4/18/2025
  • Market Cap

    16.09B

  • Enterprise Value

    18.61B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.35

  • Price/Book (mrq)

    1.44

  • Enterprise Value/Revenue

    1.58

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.49%

  • Return on Assets (ttm)

    1.75%

  • Return on Equity (ttm)

    -4.04%

  • Revenue (ttm)

    11.78B

  • Net Income Avi to Common (ttm)

    -293.31M

  • Diluted EPS (ttm)

    -0.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.31B

  • Total Debt/Equity (mrq)

    36.39%

  • Levered Free Cash Flow (ttm)

    1.19B

Research Analysis: 603858.SS

View More

Company Insights: 603858.SS

Research Reports: 603858.SS

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.